Your Nerves Are Burning and You Don't Have Diabetes. Here's Why.

COMT encodes an enzyme that breaks down dopamine, norepinephrine, and other catecholamines in your brain and nervous system. These neurotransmitters are central to your brain’s ability to inhibit pain signals coming up from your spinal cord. When COMT is working efficiently, it maintains the right balance: enough catecholamine activity to suppress pain, but not so much that you’re overstimulated.

The Val158Met variant, carried by roughly 25% of people with European ancestry as homozygotes, slows down your COMT enzyme by 25-40%. This means catecholamines stay active in your synapses longer. Sounds good, but it’s not. Slow COMT means your pain-inhibition system is always partially “on,” creating a state of constant neurological vigilance that amplifies pain signal transmission in your spinal cord and brain. You develop what’s called central sensitization: your nervous system interprets routine sensory input as dangerous and cranks up the alarm.

You notice this as tingling and burning that seems to come out of nowhere, worsens with stress, and is worse at night when your nervous system has nothing else to focus on. You’re hypersensitive to touch, temperature, and light. You might also experience brain fog, anxiety, or difficulty concentrating because the same slow COMT that amplifies pain also leaves dopamine elevated in your prefrontal cortex.

MTHFR encodes the enzyme that converts folate into methylfolate, the active form your cells actually use. This gene is involved in more than just methylation; it directly controls nitric oxide (NO) production in your blood vessels. Nitric oxide regulates vascular tone, blood flow, and inflammation in nerve tissue. Your peripheral nerves depend on steady blood flow to stay healthy.

The C677T variant, present in roughly 40% of people with European ancestry, reduces MTHFR enzyme activity by 40-70%. This means two things happen: your cells can’t methylate efficiently, and your vascular endothelium produces less nitric oxide. Your peripheral nerves receive reduced blood flow, accumulate metabolic waste, and become irritable and inflamed. Simultaneously, elevated homocysteine (a byproduct of impaired methylation) is directly toxic to nerve cells and promotes vascular inflammation.

You experience burning and tingling that often worsens in cold weather or after physical exertion because your nerves are already underperfused. You might also have cold hands and feet, slow wound healing, and symptoms that improve when you’re warm or moving around (because you’re forcing blood flow through sheer activity).

VDR encodes the vitamin D receptor, the molecular switch that determines whether vitamin D actually signals your cells to reduce inflammation and promote nerve repair. Vitamin D is not just a bone nutrient; it’s a potent immunomodulator. Your peripheral nerves are wrapped in a sheath of immune cells that produce inflammatory cytokines. If your VDR doesn’t work efficiently, vitamin D can’t tell these immune cells to stand down.

The FokI polymorphism and other VDR variants are carried by roughly 30-40% of the population depending on ancestry. The “ff” short allele variant reduces VDR expression and sensitivity to vitamin D signaling. Your immune cells stay in a state of chronic low-grade activation, continuously releasing inflammatory molecules like TNF-alpha and IL-6 that irritate nerve tissue. Even if your vitamin D blood level is technically “normal,” your cells aren’t responding to it.

You notice burning and tingling that flares in winter, worsens with infections or stress, and feels like your nerves are “raw” or hypersensitive. You might also have muscle aches, poor wound healing, and frequent minor infections because your immune regulation is impaired.

SOD2 encodes superoxide dismutase 2, an enzyme that lives inside your mitochondria and neutralizes free radicals before they damage your cell’s DNA and proteins. Your peripheral nerve cells are metabolically demanding; they burn a lot of ATP to maintain the electrical gradients that fire action potentials. High metabolism means high oxidative stress. If your SOD2 doesn’t work efficiently, reactive oxygen species (ROS) accumulate and damage the proteins and lipids that make up your nerve cell membranes.

The Ala16Val variant, present in roughly 25-35% of the population, reduces SOD2 enzyme activity by 20-40%. This means your nerve cells are chronically exposed to free radical damage. Over time, oxidative stress damages the proteins in your nerve cell membranes, impairs mitochondrial ATP production, and creates chronic neuronal inflammation. Your nerves become progressively more irritable and start sending false alarm signals.

You experience tingling and burning that worsens with exertion, improves with rest, and may be accompanied by fatigue or difficulty concentrating. Your symptoms might also worsen with any kind of inflammatory trigger: inflammatory foods, poor sleep, stress, or minor infections.

OPRM1 encodes the mu-opioid receptor, the cellular switch that responds to your body’s endogenous opioids: endorphins and enkephalins. These molecules are your nervous system’s built-in pain relief. When you experience pain, your brain and spinal cord release endogenous opioids to dampen the pain signal. When your mu-opioid receptor works well, this system is highly effective. When it doesn’t, pain signals pass through unfiltered.

The A118G variant (rs1799971), carried by roughly 10-15% of people with European ancestry (and up to 40% in East Asian populations), reduces mu-opioid receptor sensitivity to endogenous opioids. Your brain releases the same amount of endorphins and enkephalins as everyone else, but your nerve cells don’t respond to them as effectively. You’re left with a pain-relief system that’s running but not delivering the signal.

You experience tingling and burning that doesn’t respond well to exercise, meditation, or other natural pain-relief triggers that work for other people. You might notice that minor injuries hurt more than they should, that you recover slowly from pain, and that your pain seems to spiral more easily into chronic states.

FAAH encodes fatty acid amide hydrolase, an enzyme that breaks down anandamide, your body’s natural endocannabinoid. Anandamide is sometimes called “the bliss molecule” because it activates cannabinoid receptors in your brain and spinal cord, reducing pain perception and promoting calm. Your body produces anandamide constantly; FAAH determines how long it stays active before being metabolized away.

The C385A variant (rs324420), carried by roughly 20-30% of the population, reduces FAAH enzyme activity. This means anandamide stays in your synapses longer. People with this variant experience naturally higher anandamide levels, which translates to lower pain sensitivity and a greater capacity to modulate pain signals. You should theoretically have less neuropathic pain. But if you also carry variants in other pain genes (COMT, MTHFR, SOD2, or OPRM1), the FAAH variant alone may not be enough to overcome the other genetic liabilities.

You might notice that THC-containing cannabis affects you differently than other people (often more strongly), and that you’re sensitive to other cannabinergic compounds. Your natural pain threshold might be decent in baseline conditions, but tingling and burning still emerges under stress or inflammatory conditions because the other genetic factors override your anandamide advantage.